NAS:FATE (USA) Also trade in: Germany

Fate Therapeutics Inc

$ 18.82 0 (0%)
Volume: 440,466 Avg Vol (1m): 708,854
Market Cap $: 1.23 Bil Enterprise Value $: 1.06 Bil
P/E (TTM): 0.00 P/B: 8.36
Earnings Power Value -2.5
Net Current Asset Value 1.72
Tangible Book 2.25
Projected FCF -3.57
Median P/S Value 3.76
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 12.29
Cash-To-Debt ranked lower than
61.22% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
FATE: 12.29
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.74, Med: 4.62, Max: 56.32
Current: 12.29
0.74
56.32
Equity-to-Asset 0.66
Equity-to-Asset ranked lower than
58.19% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
FATE: 0.66
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -4.77, Med: 0.62, Max: 0.79
Current: 0.66
-4.77
0.79
Debt-to-Equity 0.10
Debt-to-Equity ranked lower than
51.20% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
FATE: 0.1
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -18.05, Med: 0.17, Max: 0.93
Current: 0.1
-18.05
0.93
Debt-to-EBITDA -0.22
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
FATE: -0.22
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.79, Med: -0.35, Max: -0.09
Current: -0.22
-0.79
-0.09
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.66
DISTRESS
GREY
SAFE
Beneish M-Score 27.39
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 19.4%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -1157.96
Operating Margin ranked lower than
78.28% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
FATE: -1157.96
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1820.29, Med: -1136.15, Max: -507.75
Current: -1157.96
-1820.29
-507.75
Net Margin % -1138.09
Net Margin ranked lower than
79.29% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
FATE: -1138.09
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -2151.8, Med: -1147.61, Max: -533.3
Current: -1138.09
-2151.8
-533.3
ROE % -60.48
ROE ranked lower than
73.71% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
FATE: -60.48
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -90.37, Med: -60.19, Max: -56.05
Current: -60.48
-90.37
-56.05
ROA % -43.49
ROA ranked lower than
72.51% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
FATE: -43.49
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -171, Med: -49.42, Max: -41.06
Current: -43.49
-171
-41.06
ROC (Joel Greenblatt) % -1542.20
ROC (Joel Greenblatt) ranked lower than
69.21% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
FATE: -1542.2
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -2520.8, Med: -1696.8, Max: -1248.48
Current: -1542.2
-2520.8
-1248.48
3-Year Total Revenue Growth Rate 24.90
3-Year Revenue Growth Rate ranked lower than
100.00% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
FATE: -4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -64.7, Max: -4
Current: -4
0
-4
3-Year Total EBITDA Growth Rate -33.00
3-Year EBITDA Growth Rate ranked higher than
53.62% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
FATE: -2.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -2.1, Med: 33.5, Max: 56.9
Current: -2.1
-2.1
56.9
3-Year EPS w/o NRI Growth Rate -0.30
3-Year EPS w/o NRI Growth Rate ranked higher than
51.38% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
FATE: -0.3
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -0.3, Med: 15, Max: 57.2
Current: -0.3
-0.3
57.2

» FATE's 30-Y Financials

Financials (Next Earnings Date: 2019-08-06)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:FATE

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2836
Compare NAS:GOSS NAS:ALDR NAS:EPZM SZSE:300204 XMAD:ROVI NAS:ESPR NAS:CHRS SZSE:300149 SZSE:000403 NAS:SPPI SZSE:300255 NAS:AUTL NAS:CDXS XKRX:298380 NAS:IFRX HKSE:06826 XTER:BIO3 SZSE:002275 NAS:NGM NAS:PBYI
Traded in other countries F6T.Germany
Address 3535 General Atomics Court, Suite 200, San Diego, CA, USA, 92121
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company which develops programmed cellular immunotherapies for cancer and immune disorders. It uses pharmacologic modulators, such as small molecules, to enhance the biological properties and therapeutic function of cells ex vivo before the product candidates are administered to a patient. In other cases, it uses human induced pluripotent stem cells (iPSCs), generates a master iPSC line having preferred biological properties, and direct the fate of the iPSC line to create a clonal population.

Ratios

Current vs industry vs history
PB Ratio 8.36
PB Ratio ranked lower than
83.99% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
FATE: 8.36
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.17, Med: 3.17, Max: 13.27
Current: 8.36
1.17
13.27
PS Ratio 179.25
PS Ratio ranked lower than
87.33% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
FATE: 179.25
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 7.61, Med: 35.82, Max: 532.86
Current: 179.25
7.61
532.86
EV-to-EBIT -15.01
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
FATE: -15.01
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -15.5, Med: -3.2, Max: 0.1
Current: -15.01
-15.5
0.1
EV-to-EBITDA -15.31
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
FATE: -15.31
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -15.8, Med: -3.3, Max: 0.1
Current: -15.31
-15.8
0.1
EV-to-Revenue 166.82
EV-to-Revenue ranked lower than
83.27% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
FATE: 166.82
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -0.8, Med: 101.3, Max: 509.6
Current: 166.82
-0.8
509.6
Current Ratio 6.40
Current Ratio ranked higher than
53.82% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
FATE: 6.4
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.75, Med: 6.54, Max: 11.88
Current: 6.4
0.75
11.88
Quick Ratio 6.40
Quick Ratio ranked higher than
55.77% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
FATE: 6.4
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.75, Med: 6.54, Max: 11.88
Current: 6.4
0.75
11.88
Days Sales Outstanding 28.76
Days Sales Outstanding ranked higher than
68.56% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
FATE: 28.76
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 28.76, Med: 38.5, Max: 38.5
Current: 28.76
28.76
38.5

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -25.10
3-Year Share Buyback Rate ranked lower than
79.23% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
FATE: -25.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -191.4, Med: -36.8, Max: -25.1
Current: -25.1
-191.4
-25.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 8.36
Price-to-Tangible-Book ranked lower than
77.85% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
FATE: 8.36
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.42, Med: 3.64, Max: 11.68
Current: 8.36
1.42
11.68
Price-to-Median-PS-Value 5.01
Price-to-Median-PS-Value ranked lower than
92.48% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
FATE: 5.01
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.22, Med: 1.08, Max: 12.94
Current: 5.01
0.22
12.94
Earnings Yield (Joel Greenblatt) % -6.66
Earnings Yield (Greenblatt) ranked lower than
55.41% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
FATE: -6.66
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -1409.1, Med: -30.6, Max: 1354.5
Current: -6.66
-1409.1
1354.5

More Statistics

Revenue (TTM) (Mil) $ 6.35
EPS (TTM) $ -1.23
Beta 2.85
Volatility % 70.88
52-Week Range $ 8.64 - 20.04
Shares Outstanding (Mil) 65.19

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y